Loading…
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
Highlights ► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.
Saved in:
Published in: | Vaccine 2012-11, Vol.30 (48), p.6918-6926 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Highlights ► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2012.08.057 |